Quest PharmaTech Ownership
| QPT Stock | CAD 0.04 0.01 33.33% |
Shares in Circulation | First Issued 2017-03-31 | Previous Quarter 169.1 M | Current Value 169.1 M | Avarage Shares Outstanding 166 M | Quarterly Volatility 5.5 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Quest |
Quest Stock Ownership Analysis
About 17.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.29. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Quest PharmaTech recorded a loss per share of 0.02. The entity last dividend was issued on the 21st of July 2005. Quest PharmaTech Inc., a biotechnology company, develops and commercializes antibody based immunotherapeutic products for cancer. The company also owns the Photodynamic therapy technology for oncology and dermatology applications and develops Mab AR 9.6 against truncated O-glycan on MUC16 for targeted cancer therapy applications. QUEST PHARMATECH operates under Biotechnology classification in Canada and is traded on TSX Venture Exchange. To find out more about Quest PharmaTech contact Ragupathy Madiyalakan at 780 448 1400 or learn more at https://www.questpharmatech.com.Quest PharmaTech Outstanding Bonds
Quest PharmaTech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Quest PharmaTech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Quest bonds can be classified according to their maturity, which is the date when Quest PharmaTech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Quest Stock Analysis
When running Quest PharmaTech's price analysis, check to measure Quest PharmaTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quest PharmaTech is operating at the current time. Most of Quest PharmaTech's value examination focuses on studying past and present price action to predict the probability of Quest PharmaTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quest PharmaTech's price. Additionally, you may evaluate how the addition of Quest PharmaTech to your portfolios can decrease your overall portfolio volatility.